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Abstract
Background: Most of  patients experience pain during the panretinal photocoagulation(PRP). Laser photocoagulation delivery 
has advanced with the introduction of  pattern-scanning laser systems (PASCAL). Shorter pulse duration and less choroidal pen-
etration believed to reduce pain during the laser treatment.
Objectives: To compare the severity of  expressed pain scores in patients with PDR who underwent PRP either with PASCAL 
laser or conventional laser.
Methods: A total of  28 patients with a diagnosis of  PDR who were scheduled for bilateral PRP therapy were enrolled into the 
prospective study. Both eyes were treated within the same session and while one eye was treated with PASCAL the other was 
treated with conventional laser randomly. Pulse duration was adjusted to 100-ms in conventional laser and 30 ms in PASCAL. 
The severity of  pain was graded using a verbal scale and a visual analog scale (VAS).  
Results: Mean age was 61.36±9.10 years. Mean verbal and VAS scores were 1.32±0.47 and 2.86±1.21 in the PASCAL laser and 
2.39±0.49 and 5.75±1.35 in the conventional laser group, respectively. Differences between expressed pain scores obtained by 
both two scales were statistically significant (p<0.001).
Conclusion: PASCAL laser significantly alleviates pain levels possibly due to the shorter laser pulse duration and lower intensity. 
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Proliferative diabetic retinopathy (PDR) is a severe com-
plication of  diabetes mellitus characterized by new ves-
sel formation in the retina and optic disc. Tight glycemic 
control and laser treatment in the early phases of  the dis-
ease may slow the progression of  PDR.1-3 Panretinal pho-
tocoagulation (PRP) is a laser-based treatment modality 
that destroys the outer retina layers and thereby improves 
the oxygen supply of  the inner retina. During the follow-
ing years, sequential improvements took place, including 
introduction of  yellow, green, and diode lasers with vari-
ous advantages of  each wavelength.4
In 2006, a novel semi-automatic and multi-shot photoco-
agulator called as PASCAL (Pattern scan laser, Opti-Med-
ica Corp., Santa Clara, California, USA) was introduced 
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with a reduction in pulse duration of  each laser spot from 
typical 100 ms down to 10-30 millisecond. Compared 
with the conventional laser, shorter pulses have been 
shown to significantly reduce the risk of  damage to the 
adjacent retinal tissues.5,6
Almost all patients experience pain during PRP. While 
some patients may tolerate the pain, the majority does 
not.7 One study reported that 64.1% of  patients did not 
complete treatment due to pain and therefore had an 
increased risk of  vision loss.8 To improve patient com-
pliance, several anesthetic and analgesic techniques such 
as peribulbar anesthesia, oral anesthesia and topical eye 
drops have been used.9-11 The patient comfort, and thus 
compliance, may be improved by using the shorter ex-
posure burns, avoiding red or infrared wavelengths with 
deeper penetration, and by decreasing overall treatment 
time.
In the current study we aimed to compare the severity of  
expressed pain scores in patients with PDR who under-
went either PASCAL or conventional laser. Additionally 
we assessed the association between patient characteris-
tics and severity of  pain. 
Methods
This prospective study included a total of  28 patients 
with a diagnosis of  PDR who were scheduled for bilat-
eral PRP therapy. Inclusion criteria comprised patients 
(>18 years) with type 1 or 2 diabetes and bilateral high-
risk proliferative diabetic retinopathy (PDR), which was 
defined as the presence of  neovascularization (NVD) at 
the disc, presence of  NVD associated with vitreous or 
preretinal hemorrhage, or neovascularization elsewhere 
of  more than half  the disc area associated with vitreous 
or preretinal hemorrhage.
Patients with a history of  focal/grid photocoagulation, 
a history of  orbital trauma, orbital infection or surgery, 
those with corneal or lens opacities, those with vitreous 
hemorrhage and non-compliant patients were excluded 
from the study. This study was conducted in accordance 
with tenets of  the Declaration of  Helsinki and institu-
tional review board approval was obtained from Local 
Ethics Committee. Informed consent was obtained from 
all participants. The name of  the registry and the regis-
tration number is ClinicalTrials.gov, ID: NCT02645383.
All participants underwent comprehensive ophthalmic 
examinations, including visual acuity testing, slit-lamp 
biomicroscopy, intraocular pressure measurement using 
Goldmann applanation tonometer, and dilated fundo-
scopic examination. Color fundus photographs and flu-
orescein angiography were performed at baseline before 
laser photocoagulation.
We usually finish the full PRP of  one eye in four session. 
One of  these sessions was used for this study. Due to 
study circumstances, the session that was be used for this 
study was not prolonged and the session was completed 
in a shorter duration than the others to keep both eyes 
of  the patient under the treatment in this session. There-
fore the number of  laser shots was less than in the usual 
PRP session. Consequently, both eyes were treated with-
in the same session and while one eye was treated with 
PASCAL laser, the other was treated with conventional 
laser (ELLEX Integre, Adailade, Australia) with 30 min-
utes resting intervals. To avoid a bias about orientation or 
becoming accustomed to laser procedure, PASCAL laser 
was performed in the first eyes in half  of  the patients 
(14 patients) and conventional laser was performed in the 
first eyes in the other half  of  the patients randomly (Fig-
ure 1). 
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Figure 1: Participant flow through study 
While the spot size used to obtain a white-grayish spot on 
the retina was 200-400 µm in both PASCAL and conven-
tional laser, the pulse duration was 100 ms with conven-
tional laser and 30ms with PASCAL laser. In order to ac-
curately and reliable compare the grade of  pain between 
each procedures, we tried to standardize the retinal areas 
and total number of  spots delivered. Similar numbers of  
laser spots were created by two laser systems in similar 
retinal quadrants in both eyes. Thirty minutes after the 
procedure ended the severity of  pain was assessed us-
ing a verbal rating scale and a visual analog scale (VAS). 
In the verbal scale the patient rates the pain on a Likert 
scale verbally, e.g. "none", "mild pain", "moderate pain", 
"severe pain" or "very severe pain" in five grading system 
(0-4) and in the VAS they specify the severity of  pain by 




Figure 2: Visual Analog Scale 
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Using these scores we assessed the relationship between 
severity of  pain and patient characteristics including his-
tory of  prior PRP treatment (experience), gender and du-
ration of  diabetes mellitus. Patients were assigned either 
in the experienced or non-experienced groups depending 
on history of  prior PRP. The person who performed the 
VS and VAS tests was blinded for the laser machine used 
in each eye.
Statistical analyses were performed using the SPSS (Statis-
tical Package for Social Sciences Inc., Chicago, IL, ABD) 
17.0 software. Distribution of  data was assessed by the 
Shapiro-Wilk test. Comparison was undertaken using the 
Mann-Whitney U test. The minimal significance (α) and 
statistical power (1- β) were set at 0.05 and 0.80 respec-
tively.
Results
Mean age was 61.36±9.10 years and mean diabetes du-
ration was 9.84±6.96 (minimum 0.25 - maximum 27.5) 
years. The mean number of  laser spots delivered did not 
significantly differ between the PASCAL and convention-
al laser groups (435.36±77.46 vs. 436.18±74.63; p=0.76). 
The mean PRP duration was significantly shorter in the 
PASCAL vs. conventional laser group (3.76±0.48 min vs. 
6.65±0.98 min; p<0.001).
Mean verbal and VAS scores were 1.32±0.47 and 
2.86±1.21 in the PASCAL laser and 2.39±0.49 and 
5.75±1.35 in the conventional laser group, respectively. 
Pain scores obtained from both assessments were signifi-
cantly lower in patients in the PASCAL group (p<0.001) 
(Table 1). 
Number of  experienced vs. non-experienced patients 
was 17 (%60.7) and 11 (%39.3), respectively. Mean ver-
bal and VAS scores were both significantly lower in ex-
perienced vs. non-experienced patients in the PASCAL 
group [(1.12±0.33) and (2.35±0.93) vs. (1.64±0.5) and 
(3.64±1.21); (p: 0.005 and 0.009, respectively)] as well 
as in the conventional laser group [(2.24±0.44) and 
(5.29±1.21) vs. (2.64±0.5) and (6.45±1.29); (p: 0.037 and 
0.027, respectively)] (Figure 3). 
 
 
Figure 3: Pain scores in experience and inexperienced patients  
on previous laser treatments; VAS: Visual Analog Scale 
Table 1: Pain scores in patients 
 





Verbal Score 1.32±0.47 2.39±0.49 <0.001 
VAS 2.86±1.21 5.75±1.35 <0.001 
 
VAS: Visual Analog Scale; p:Mann-Whitney U test 
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Of  the enrolled patients 12 (42.9%) were females and 16 
(57.1%) males.  While female patients scored higher for 
verbal scale and VAS in each of  the PASCAL and con-
ventional laser groups, the difference reached statistical 
significance only in the PASCAL group (p: 0.08 and 0.02, 
respectively) (Table 2).
Table 2: Pain scores according to gender 
 





PASCAL-Verbal Score 1.50±0.52 1.19±0.40 0.08 
Conventional-Verbal 
Score 
2.42±0.51 2.38±0.50 0.83 
PASCAL-VAS 3.50±1.69 2.38±1.02 0.02 
Conventional-VAS 5.92±1.44 5.63±1.31 0.59 
 
VAS: Visual Analog Scale; p:Mann-Whitney U test 
In the conventional laser group, patients with diabetes 
duration longer than 120 months had significantly lower 
verbal scale and VAS pain scores than those with diabe-
tes duration less than 120 months (p:0. 003 and 0.001, 
respectively). In the PASCAL group, however, the differ-
ence was not significant (Table 3). 
Table 3: Pain scores according to duration of DM 
 
  DM ≤120 months 
n=13 
DM >120 months 
n=15 
p 
PASCAL-Verbal Score 1.31±0.48 1.33±0.49 0.889 
Conventional-Verbal 
Score 
2.69±0.48 2.13±0.35 0.003 
PASCAL-VAS 3.08±1.12 2.67±1.29 0.365 
Conventional-VAS 6.69±1.25 4.93±0.79 0.001 
 
GAS: Visual Analog Scale; DM: Diabetes Mellitus; p:Mann-Whitney U test 
Correlation analysis revealed significant correlation be-
tween verbal scores and history of  laser photocoagulation 
(LFC) and number of  burns, as well as between VAS scores 
and gender, history of  LFC and number of  burns in the 
PASCAL group (r=-0.542,p=0.003, r=0.453,p=0.015 r=-
0.469,p=0.012, r=-0.528,p=0.004, r=0.533,p=0.004, re-
spectively). Similarly significant correlation was observed 
between both verbal and VAS scores and duration of  
DM, history of  LFC and number of  burns in the conven-
tional laser group (r=-0.500,p=0.007, r=-0.401,p=0.034, 
r=0.514,p=0.005 r=-0.469,p=0.012, r=-0.427,p=0.023, 
r=0.518,p=0.005, respectively). 
Discussion
In our study, PASCAL laser platforms showed signifi-
cantly less laser-induced pain compared to conventional 
diode pumped laser system in patients with PDR in a set-
ting of  bilateral, crossover, limited PRP study design. It 
is well recognized that PRP treatment decreases the risk 
of  vision loss in patients with severe PDR.12 Appropriate 
medical treatment and clinical follow-up may reduce the 
risk of  diabetes related vision loss by 90%.13 PRP may be 
significantly painful and may cause discomfort in some 
patients and it may, therefore, be interrupted due to intol-
erance to pain. Consequently, patients experiencing pain 
in the first PRP session may miss the next due to the fear 
of  recurrence of  the same pain. By altering some laser 
parameters, e.g. duration of  laser pulse, however, this-
treatment modality may prove more comfortable and less 
painful.14 But, very short pulse durations in conventional 
single spot lasers, may causes ineffective spots. 
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Although same retinal quadrants were treated and the 
mean number of  laser pulses delivered did not signifi-
cantly differ between two groups, verbal and VAS pain 
scores were significantly lower in patients in the PASCAL 
laser than in the conventional laser group. We consider 
that this difference probably was due to a shorter laser 
pulse as well as different laser technology in the PASCAL 
platform.
The thermal energy produced during PRP may, depend-
ing on the duration of  the procedure, cause collateral 
damage to adjacent tissues. Long pulse duration used 
during conventional laser application (100-200 ms) may 
cause larger scars in the retinal tissue and thereby may in-
crease retinal pigment epithelium (RPE) damage.15,16 The 
PASCAL laser technique uses shorter pulses as compared 
with conventional laser. It is possible that decreasing the 
pulse duration from mili- to microseconds alleviates pain. 
Targeting the retinal pigment epithelium while preserv-
ing adjacent photoreceptors through micro-air bubble 
formation formed around melanosomes is a novel target 
therapy modality of  laser photocoagulation. The critical 
threshold between thermal and mechanical damage is 50 
ms.17-19 In conventional lasers, it is not possible to use 
shorter pulse duration shorter than 100 ms in 200 micron 
or larger shots. Shorter pulses used during PASCAL laser 
cause mechanical rupture but not thermal damage, due 
to the formation of  transient vapor bubbles. The dam-
age is thereby, limited to the retinal pigment epithelium 
and outer retinal layers and does not extend to the inner 
retinal layers and sensory-rich chorioretinal tissues. This 
condition has the potential to decrease pain because both 
vertical and axial scaring will decrease and hence will limit 
collateral damage to the retina and increase preservation 
of  retinal sensitivity.20
A recent study reported that the total time of  PRP du-
ration was significantly shorter with PASCAL laser than 
with conventional laser.21 Our results confirmed this find-
ing. Shortening of  the total time is also critical in that it 
may increase compliance due to pain relief. 
Long laser pulse duration in conventional laser is associ-
ated with more severe pain and increased rate of  photo-
phobia following laser therapy. Local ocular inflammato-
ry response may increase retinal neurogenic inflammation 
in pain transmitting nerve cells and thereby may increase 
the intensity of  pain. Muqit et al.22 reported that intraret-
inal inflammation and the severity of  pain was higher in 
patients who were treated with 100 ms single spot con-
ventional laser as compared with 20 ms multi-spot PAS-
CAL laser.
One may be concerned that while shorter duration of  
laser pulse with PASCAL laser alleviates pain, it may also 
cause under treatment. Studies from the literature, how-
ever, have consistently shown that treatment efficacy was 
similar between PASCAL and conventional laser treat-
ment.20,23
The perception of  pain during PRP may vary from pa-
tient to patient and it may be influenced by many factors 
such as the pain threshold, cultural differences, degree 
of  fundus pigmentation, history of  prior laser treatment, 
anxiety and gender.20 In the current study, mean verbal 
and VAS scores were significantly lower in experienced 
vs. non-experienced patients in both the PASCAL and 
conventional laser groups, confirming that experience is 
an important factor associated with post-operative pain. 
Several studies reported that the threshold of  pain was 
lower in women.24 In addition, it was detected that retinal 
thickness is thinner in women than in men. Some ocu-
lar distinctions between men and women such as retinal 
and choroidal thickness, ocular blood flow and hormonal 
differences may be related to pain score differences.25,26 
In the current study we found a significant relationship 
between gender and the severity of  pain in the PASCAL 
group and also between diabetes duration and severity of  
pain in the conventional laser group. It is well recognized 
that patients with diabetes may experience silent myocar-
dial infarction due to the damage occurring on the senso-
ry fibers implicated in pain processing.27 A similar path-
way may have caused damage to the retinal pain neurons 
and therefore patients with longer duration of  diabetes 
may have felt less intense pain. Additionally, the fact that 
pain perception is a subjective and personal experience, 
sociocultural differences may, in part, have accounted for 
the difference in the perception of  pain reported among 
individuals.
The limitations of  our current study include the small pa-
tient series and while the relatively small number of  spots 
delivered may appear to be a limitation, the main purpose 
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of  the study was to compare pain responses and not to 
compare treatment efficacy. Additionally, we followed all 
patients and performed the second to fourth treatment 
sessions after one week at the latest and eventually com-
pleted PRP treatments within one month.
Conclusion  
Due to shorter laser pulse and lower intensity or the dif-
ferent technology used, PASCAL platform provides sig-
nificant alleviation of  pain during PRP and, therefore, 
may increase compliance. 
The name of  the registry and the registration number is 
ClinicalTrials.gov, ID: NCT02645383.
This study was presented at 48th TOD National Congress, 
5-9 November 2014, Antalya,Turkey.
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